🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Technology Sector SEC Filings — September 29, 2026

The seven filings for the S&P 500 Technology stream are dominated by Apple Inc., with six filings detailing restricted stock unit (RSU) awards to its top executives, including the CEO, CFO, COO, and Chair. This concentrated insider activity signals a strong, standardized retention strategy, with no insider selling detected, which is a bullish indicator for management conviction. The sole non-Apple filing from Arista Networks shows its CEO executing a substantial pre-planned stock sale, a bearish signal that warrants monitoring for potential sector-wide insider selling patterns. No period-over-period financial comparisons, forward-looking guidance, or capital allocation changes were present in the enriched data, limiting trend analysis but highlighting a period of operational stability and executive compensation alignment. The primary actionable intelligence centers on insider trading dynamics, with Apple's RSU awards reinforcing a long-term hold thesis, while Arista's CEO sale introduces a cautionary note for that specific company.

1 high priority 6 medium 7 total filings
· daily

Nasdaq 100 Stocks SEC Filings — September 29, 2026

The September 29, 2026 filing batch for the NASDAQ-100 stream is dominated by insider equity compensation activity at mega-cap technology leaders Apple and Alphabet, alongside a major liquidity enhancement at Tesla. The period-over-period data reveals a synchronized pattern of routine, tax-motivated insider selling at Alphabet (total ~$6.4M) and significant RSU grants at Apple, which we interpret as standard compensation events rather than bearish signals. Tesla's $30B credit facility restructuring, replacing a $5B revolver, signals a defensive liquidity posture and potential strategic optionality, despite no immediate drawdown plans. The absence of operational or financial guidance in these filings limits fundamental trend analysis, shifting focus to capital structure, insider behavior, and forward-looking catalysts. The overall theme is one of large-cap financial engineering and management wealth alignment, with no signs of distress but also no aggressive bullish signals from insiders.

1 high priority 13 medium 14 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — September 29, 2026

The 27 filings reveal a surge in activist campaigns targeting underperformers across real estate, consumer, and tech sectors, with major shareholders pushing for strategic alternatives such as sales, board changes, or operational improvements. Notable insider buying by Ryan Cohen (GameStop) and Oasis Management (Vail Resorts) signals conviction at depressed prices, while insider selling by IFC (Lesaka Technologies) and KE Holdings' founder raises caution. SPAC activity is reviving with new sponsors for NorthStrive and BEST SPAC, and M&A catalysts are emerging at MoneyHero, IAC, and Lifecore Biomedical. Passive institutional stakes in Maravai LifeSciences, Sweetgreen, and Coursera indicate selective sector interest. The most critical developments are the activist escalation at BrightSpire Capital after board rejection of ownership waiver, the public letter from MoneyHero's largest unaffiliated shareholder urging a sale, and the completion of Global Business Travel Group's merger at $9.50/share.

18 high priority 9 medium 27 total filings
· daily

S&P 500 Financials Sector SEC Filings — September 29, 2026

The six filings from the S&P 500 Financials sector reveal a period of significant leadership and capital structure transitions, with insider trading activity providing mixed signals. Notably, two major insider sales—from Berkshire Hathaway’s Vice Chairman ($20M) and AFLAC’s 10% owner ($1.33M)—suggest potential bearish conviction or portfolio rebalancing, though AFLAC’s sale was under a 10b5-1 plan, mitigating alarm. Northern Trust’s CFO retirement and Morgan Stanley Direct Lending’s director resignation indicate ongoing board-level churn, while PNC’s $525M preferred stock redemption and T. Rowe Price’s steady fund distributions point to routine capital management. No period-over-period financial comparisons were available in these filings, limiting trend analysis, but forward-looking statements from Northern Trust (CFO transition through Q1 2027) and PNC (redemption Nov 2, 2026) create near-term catalysts. The overarching theme is one of stability amidst transition, with insider sales warranting close monitoring for follow-on moves.

4 high priority 2 medium 6 total filings
· daily

S&P 500 Energy Sector SEC Filings — September 29, 2026

The 7 filings from the USA S&P 500 Energy stream are dominated by insider trading disclosures at EOG Resources (4 filings) and Texas Pacific Land Corp (2 filings), with one gift filing from Occidental Petroleum. The period-over-period enriched data shows no revenue, margin, or operational trends as these are all Form 4 insider transaction filings. The key portfolio-level pattern is a stark contrast in insider behavior: EOG Resources insiders are actively selling and receiving stock awards (including a $1.27M sale by the COO under a 10b5-1 plan), while Texas Pacific Land Corp's 10% owner is making symbolic token purchases. No forward-looking guidance, capital allocation changes, or transaction details were present. The most critical development is the COO sale at EOG, which, combined with multiple insider awards, signals potential management liquidity events or diversification. The sector theme is one of mixed insider conviction—executives at EOG are monetizing equity, while TPL's major holder shows minimal incremental buying.

7 high priority 7 total filings
· daily

S&P 500 Industrials Sector SEC Filings — September 29, 2026

The sole filing in this digest, FedEx Corp's 8-K reporting its 2026 annual meeting, presents a neutral governance event with limited direct financial impact but notable shareholder sentiment signals. All 11 director nominees were elected, and management's proposals on executive compensation (90.6% approval) and auditor ratification (94.3%) passed overwhelmingly. However, three shareholder proposals were defeated, with the independent board chair proposal garnering a significant 39.2% support—a level that often precedes future activist pressure. The lack of period-over-period comparisons, insider trading, forward-looking guidance, or capital allocation data in this filing restricts the depth of trend analysis. The primary insight is the governance tension, which, while not an immediate financial catalyst, signals a potential medium-term risk for management if shareholder discontent escalates. No other filings were provided for cross-company comparison, limiting sector-wide theme identification.

1 high priority 1 total filings
· daily

US Material Events SEC 8-K Filings — September 29, 2026

The digest captures a dynamic period for the covered universe, marked by significant capital markets activity (debt raises, M&A), a clear pivot towards data centers and AI infrastructure, and notable governance changes. Key themes include aggressive balance sheet management (leverage up for M&A, down for others), a flurry of FDA-related news, and a shift in capital allocation towards share repurchases. While several companies are executing on high-growth strategies, the market is also pricing in execution risks, as seen in the wide range of outcomes from FDA decisions and the volatility in the solar and biotech sectors.

50 high priority 50 total filings
· daily

Insider Trading Pulse — September 29, 2026

Today's insider trading filings reveal a stark divergence in management conviction across the portfolio. A cluster of high-materiality insider sales at Alibaba Group (CFO sold $1.41M, General Counsel and People Officer also sold) and a massive $84.6M sale by KE Holdings' CEO signal potential bearish sentiment at the top of these firms. Conversely, a notable buying pattern emerged at Precision Biosciences, where two directors purchased shares at ~$6.27-$6.28, and at Inspira Technologies, where the CEO invested $120K at $0.71/share, suggesting strong insider confidence in these smaller-cap names. A significant volume of low-materiality, neutral filings from MFS trusts and UMH Properties indicate routine beneficial ownership reporting rather than active trading. The day's data is dominated by sales from Chinese e-commerce and tech executives, contrasting with buys from biotech and specialty finance directors, creating a clear 'sell in China tech, buy in US small-cap' narrative.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — September 29, 2026

The 13 filings for the Dow 30 stream are dominated by insider equity activity at Apple and Alphabet, and a capital structure move at Sherwin-Williams. No period-over-period financial trends, forward-looking guidance, or dividend/buyback data were present in the filings, limiting the ability to generate traditional fundamental trend analysis. The key theme is the routine, yet massive, equity compensation and tax-withholding transactions at the two mega-cap tech giants, which provide a window into insider holdings but do not signal directional conviction. Sherwin-Williams' refinancing of a $750M term loan is a neutral liquidity management event. The digest focuses on the scale of insider transactions, the lack of any bearish signals from the filings, and the neutral capital allocation move at Sherwin-Williams.

1 high priority 12 medium 13 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 29, 2026

The four filings in this intelligence stream collectively paint a picture of acute distress across a spectrum of US-listed companies, with a heavy concentration of Nasdaq non-compliance issues. The most critical development is the completed $6.3 billion take-private of Global Business Travel Group (Amex GBT), which, while a positive exit for shareholders, removes a major publicly traded entity and signals a potential trend of private equity scooping up undervalued travel-tech assets. The remaining three filings all involve Nasdaq listing deficiencies, highlighting a systemic stress point for micro-cap and pre-revenue companies. Period-over-period data, where available, shows a clear pattern of deteriorating financial health: SurgePays is fighting a bid price deficiency despite a 180-day extension, while Liminatus Pharma only regained compliance through a dilutive 1-for-50 reverse stock split, a classic sign of financial engineering rather than organic recovery. Maison Solutions is the newest entrant to the distress pool, having failed to file its annual and quarterly reports, suggesting potential accounting or operational issues. The portfolio-level theme is unmistakable: a rising tide of micro-cap companies are failing to meet basic exchange requirements, creating a high-risk environment where delisting and bankruptcy are increasingly probable outcomes for those unable to secure financing or execute a turnaround.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — September 29, 2026

The digest for September 29, 2026, is dominated by two major take-private transactions: the $6.3 billion acquisition of Global Business Travel Group (Amex GBT) by Long Lake Management and the $10.50/share tender offer for ACV Auctions by Copart, both of which are nearing completion. A significant theme is the ongoing stress in the SPAC market, with Bayview Acquisition Corp facing final delisting after failing to close a deal, while others like Constellation Acquisition Corp I continue to burn through extension periods. On the regulatory front, the Adani Group's consolidation of its cement businesses (ACC and Ambuja Cements) received overwhelming shareholder approval, marking a major strategic move. Insider activity is notably absent from these filings, but capital allocation actions, such as the tender offers by Golub Capital and PGIM Private Credit funds, signal a focus on shareholder returns in the private credit space. The period-over-period data reveals a stark contrast between the successful, high-premium takeovers and the struggling SPACs facing liquidation, highlighting a bifurcated market for event-driven strategies.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — September 29, 2026

Today's filings reveal a bifurcated market: capital is flowing aggressively into healthcare innovation (Summit Therapeutics' $2B AstraZeneca investment, HUTCHMED's NDA submission) and nuclear/uranium plays (Uranium Energy's 157% QoQ production surge, Hennessy Capital's $1B SPAC merger with ONE Nuclear), while traditional industrials face restructuring headwinds (Westlake's $205M plant closure, Copart's flat revenue). Insider activity is mixed: Conifer Management aggressively accumulated Group 1 Automotive shares ($80.5M in September), while IFC reduced Lesaka Technologies holdings below 5%. SPAC activity remains elevated with Quartzsea seeking extension and Futurewave announcing a $400M merger. Small-cap distress persists with Bakhu Holdings (cash at $2K) and VIP Play (negative equity of $40M). Period-over-period trends highlight ChipMOS's 33% revenue growth and 118% profit surge, contrasting with Bakhu's deepening losses and Copart's stagnant top line. The overarching theme is selective capital deployment favoring high-growth biotech and energy transition, while value-oriented insider buying in auto retail suggests a contrarian opportunity.

34 high priority 16 medium 50 total filings
· daily

US Earnings Financial Results SEC Filings — September 29, 2026

This digest of 13 SEC filings reveals a market bifurcated between capital-intensive growth stories and cash-starved distress stories. The most significant portfolio-level trend is a 'cash crunch' pattern: 8 of 13 companies (Uranium Energy, Bakhu, VIP Play, Copart, Celularity, Bion, Rocky Mountains, Carnival, Singularity) reported declining cash positions, with some seeing 90%+ drops. This is occurring alongside a broad-based improvement in operating losses, suggesting companies are burning cash to restructure or invest. The nuclear energy sector (Uranium Energy Corp) shows a high-risk, high-reward profile with massive cash reserves but widening losses and volatile quarterly revenue. The most positive signals come from AAR Corp (16.6% net income growth, strong cash flow swing) and Carnival Corp (3.7% quarterly net income growth, resumed shareholder returns). The most distressed signals are from VIP Play (zero cash reserves, ceased user operations) and Singularity Future Technology (78% net loss increase, internal control failures). A key cross-cutting theme is margin compression: companies like Copart and AAR saw margins decline despite revenue growth, driven by rising SG&A and operating costs.

13 high priority 13 total filings
· daily

US Executive Compensation Proxy SEC Filings — September 29, 2026

The nine proxy filings reveal a bifurcated market: established companies like Amcor, H&R Block, and Broadridge demonstrate operational strength with double-digit EPS growth and robust shareholder returns, while several micro-caps (ABVC BioPharma, Banzai, Avalon GloboCare) are pursuing dilutive capital raises and acquisitions, signaling distress or aggressive growth strategies. Notable trends include a wave of CEO transitions (H&R Block), board refreshment (Broadridge, H&R Block), and significant M&A activity (DoubleVerify, Banzai, Amcor). Capital allocation remains shareholder-friendly with dividends and buybacks at scale, but insider activity is limited. Key catalysts include shareholder votes on mergers, equity plans, and name changes, with several deadlines in late October and November 2026. The overall sentiment is mixed, with 3 positive, 4 neutral, and 2 mixed filings, reflecting cautious optimism amid geopolitical and inflationary pressures.

9 high priority 9 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 29, 2026

The sole filing in this IPO Pipeline digest is from MNBS Acquisition Corp., a special purpose acquisition company (SPAC) seeking to raise $75 million through an initial public offering. As a blank-check company with no operating history or identified target, the filing represents a speculative capital-raising vehicle rather than an operating business. The offering structure includes units composed of shares, warrants, and rights, with standard SPAC terms including a 12-month deadline to complete a business combination. The neutral sentiment and lack of period-over-period comparisons, insider activity, or forward-looking guidance reflect the pre-operational nature of this entity. The key market implication is that SPAC IPOs continue to surface in the US market, though investor appetite for such vehicles remains cautious given historical redemption rates and regulatory scrutiny. The filing provides no actionable financial trends or management signals, as it is a blank-check company with no prior financial performance.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — September 29, 2026

The four filings in this digest highlight a significant wave of regulatory and structural stress across US-listed companies, with three of four facing Nasdaq delisting risks and one completing a going-private transaction. Notably, all three Nasdaq-related filings involve compliance failures (delinquent filings, bid price deficiencies), suggesting a pattern of small-cap distress. SurgePays and Liminatus Pharma have received extensions or regained compliance, but both face ongoing financial challenges, with SurgePays' future hinging on a potential reverse split. Maison Solutions' delinquency is the most severe, with a tight timeline to submit a compliance plan. In contrast, Global Business Travel Group's $6.3 billion acquisition by Long Lake Management represents a successful exit, with stockholders receiving a 65.1% premium. The overall sentiment is predominantly negative, with only the GBT deal offering a positive outcome, reflecting a bifurcated market where distressed small caps struggle while larger entities find strategic exits.

4 high priority 4 total filings
· daily

US Executive Officer Management Changes SEC — September 29, 2026

The September 29, 2026 batch of 43 filings reveals a pronounced wave of governance transitions, with notable CEO successions at Talen Energy, Apollo Realty Income Solutions, and NextBoat, alongside a mass board resignation at Society Pass that leaves the company without any directors. A cluster of six Kevin Shannon director resignations across Morgan Stanley and related private credit funds suggests a coordinated portfolio-level governance shift. The data shows a mix of strategic appointments (TMC, Acuity, Celularity) aimed at bolstering regulatory and AI expertise, and several CFO transitions (Northern Trust, CareCloud, Chesapeake Utilities) signaling orderly succession planning. Capital allocation remains a key theme, highlighted by Talen's $3.0B buyback program and NextBoat's equity inducement grant. Sentiment is predominantly neutral (60%), with positive sentiment concentrated in biotech and tech appointments, while negative sentiment is limited to governance crises at Society Pass and Reynaldo's. The overall picture is one of active board refreshment and strategic leadership alignment, with a few high-risk governance red flags demanding immediate attention.

43 high priority 43 total filings
· daily

US Corporate Board Director Changes SEC Filings — September 29, 2026

The 43 filings reveal a period of significant board and C-suite turnover, with notable patterns including a wave of director resignations across affiliated private credit funds (Kevin Shannon at 5 entities), a mass board exodus at Society Pass, and CEO transitions at Talen Energy, Apollo Realty Income Solutions, and NextBoat. Governance concerns are elevated at micro-caps like Reynaldo's Mexican Food (auditor scandal, retroactive resignations) and BioAtla (missed milestones, CMO departure). Positive signals emerge from strategic appointments at Aquestive, Lightwave Logic, TMC, and Acuity, aligning with AI, data center, and energy themes. Capital allocation is active, highlighted by Talen's $1.5B ASR and upsized buyback, while compensation shifts at TOP Financial and BayFirst suggest evolving governance practices. Overall, the digest reflects a market in flux with both high-risk governance situations and strategic board strengthening opportunities.

43 high priority 43 total filings
· daily

US Merger & Acquisition SEC Filings — September 29, 2026

This digest captures a day of intense M&A and SPAC activity on September 29, 2026, revealing a market bifurcated between high-stakes, high-conviction deals and distressed SPACs running out of runway. The most significant capital event is the completion of the $6.3 billion take-private of Global Business Travel Group (Amex GBT) at a 65.1% premium, signaling strong private market conviction in travel tech. However, the SPAC sector is showing severe stress: Bayview Acquisition Corp was forcibly delisted after failing to complete a merger, while Constellation Acquisition Corp I used its 8th of 11 permitted extensions, highlighting a liquidity and deadline crisis for blank-check vehicles. A notable trend is the use of stock as acquisition currency, seen in Sino Green Land Corp's two all-stock deals and Lexeo Therapeutics' mixed cash/stock purchase, suggesting companies are conserving cash amid uncertain markets. The Fox Factory divestiture of Marucci Sports for $225M, despite a $120M loss on sale, represents a strategic pivot to simplify operations and reduce debt. Insider activity is limited in these filings, but the change of control at BEST SPAC I and the director resignation at D. Boral Acquisition I Corp provide governance signals. The forward-looking catalyst calendar is packed with shareholder votes, delisting dates, and business combination deadlines that will determine the fate of several entities in the coming weeks.

20 high priority 20 total filings
· monthly

US Pre-Market SEC Filings Roundup — September 29, 2026

This overnight filing cycle reveals a market bifurcated between aggressive corporate transformation and persistent financial distress. The most significant theme is a wave of high-value M&A and strategic investments, including AAR Corp's $4.0 billion acquisition of MRO Holdings, Summit Therapeutics' $2.0 billion partnership with AstraZeneca, and Sangoma Technologies' $204 million take-private. These deals signal strong conviction in aerospace, biotech, and enterprise tech sectors. Conversely, the materials and energy sectors show a stark contrast: Uranium Energy Corp is executing a successful turnaround with surging production and a strong balance sheet, while Westlake Corp is shuttering a major European PVC plant, incurring $205 million in charges. Financial health is a key differentiator; companies like UEC and AAR are leveraging strong balance sheets for growth, while distressed entities like Bakhu Holdings, VIP Play, and Singularity Future Technology are filing late reports with worsening deficits and near-zero cash positions. Insider activity is limited but notable, with a director at C1 Fund making a small open-market purchase, offering a faint positive signal in an otherwise quiet period for management transactions. The digest is dominated by capital allocation events (M&A, buybacks, dividends) and regulatory filings, with a clear undercurrent of companies either scaling up aggressively or facing existential liquidity challenges.

27 high priority 23 medium 50 total filings